In particular, this notion is supported by clinical observations that report that AKI occurred in roughly 2–3% of the patients treated with immune checkpoint inhibitors (ICIs), such as PD-1, PD-L1, and CTLA-4 inhibitors, with a meta-analysis of data from other clinical trials supporting these findings [24,25]. The gene discussed is CTLA4; the disease is acute kidney injury.